These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11235250)

  • 1. The role of urinary assessment scores in the nursing management of patients receiving prostate brachytherapy.
    Abel LJ; Blatt HJ; Stipetich RL; Fuscardo JA; Dafoe-Lambie JC; Dorsey AT; Butler WM; Merrick GS
    Clin J Oncol Nurs; 2000; 4(3):126-9. PubMed ID: 11235250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy.
    Stone NN; Stock RG
    Brachytherapy; 2003; 2(1):32-9. PubMed ID: 15062161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy.
    Kollmeier MA; Stock RG; Cesaretti J; Stone NN
    J Urol; 2005 Mar; 173(3):808-12. PubMed ID: 15711274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study.
    Elshaikh MA; Ulchaker JC; Reddy CA; Angermeier KW; Klein EA; Chehade N; Altman A; Ciezki JP
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):164-9. PubMed ID: 15850917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson Cancer Center experience.
    Anderson JF; Swanson DA; Levy LB; Kuban DA; Lee AK; Kudchadker R; Phan J; Bruno T; Frank SJ
    Urology; 2009 Sep; 74(3):601-5. PubMed ID: 19589580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose brachytherapy for treating prostate cancer: nursing considerations.
    Colella J; Scrofine S
    Urol Nurs; 2004 Feb; 24(1):39-44, 52. PubMed ID: 15054909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictability of irritative voiding symptoms following photoselective laser vaporization of the prostate.
    Matoka DJ; Averch TD
    Can J Urol; 2007 Oct; 14(5):3710-4. PubMed ID: 17949529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of prostate size on urinary quality of life indexes following laparoscopic radical prostatectomy.
    Levinson AW; Bagga HS; Pavlovich CP; Mettee LZ; Ward NT; Link RE; Su LM
    J Urol; 2008 May; 179(5):1818-22. PubMed ID: 18353375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSA spike after brachytherapy For localized prostate cancer.
    Abel L; Zeroski D; Brammer S; Butler W; Wallner KE; Merrick GS
    Urol Nurs; 2007 Dec; 27(6):507-10, 518; quiz 511. PubMed ID: 18217533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic dose-feedback prostate brachytherapy in patients with large prostates and/or planned transurethral surgery before implantation.
    Acher PL; Popert R; Morris SL; Potters L; Austin-Smith SL; Johnson UH; Nichol JE; Beaney RP
    BJU Int; 2007 May; 99(5):1066-71. PubMed ID: 17233801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term urinary sequelae following 125iodine prostate brachytherapy.
    Crook J; Fleshner N; Roberts C; Pond G
    J Urol; 2008 Jan; 179(1):141-5; discussion 146. PubMed ID: 17997424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low morbidity following high dose rate brachytherapy in the setting of prior transurethral prostate resection.
    Peddada AV; Jennings SB; Faricy PO; Walsh RA; White GA; Monroe AT
    J Urol; 2007 Nov; 178(5):1963-7. PubMed ID: 17868718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of long-term quality of life and voiding function of patients treated with radical prostatectomy or permanent brachytherapy for prostate cancer.
    Bradley EB; Bissonette EA; Theodorescu D
    BJU Int; 2004 Nov; 94(7):1003-9. PubMed ID: 15541117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate brachytherapy can be performed in selected patients after transurethral resection of the prostate.
    Moran BJ; Stutz MA; Gurel MH
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):392-6. PubMed ID: 15145153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
    Neill M; Studer G; Le L; McLean M; Yeung I; Pond G; Crook JM
    Brachytherapy; 2007; 6(3):173-9. PubMed ID: 17681239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.
    Lehrer S; Cesaretti J; Stone NN; Stock RG
    BJU Int; 2006 Nov; 98(5):979-81. PubMed ID: 17034599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.
    Ferrer M; Suárez JF; Guedea F; Fernández P; Macías V; Mariño A; Hervas A; Herruzo I; Ortiz MJ; Villavicencio H; Craven-Bratle J; Garin O; Aguiló F;
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):421-32. PubMed ID: 18325680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.
    Keyes M; Miller S; Moravan V; Pickles T; McKenzie M; Pai H; Liu M; Kwan W; Agranovich A; Spadinger I; Lapointe V; Halperin R; Morris WJ
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1023-32. PubMed ID: 19111402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.